SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical
Biotech failure, 2002
An SI Board Since January 2002
Posts SubjectMarks Bans
130 20 0
Emcee:  Miljenko Zuanic Type:  Unmoderated
Introduction Compact
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
ReplyMessage PreviewFromRecsPosted
55IRVINE, Calif., April 29 /PRNewswire-FirstCall/ -- NeoTherapeutics, Inc. (Nasdaqnigel bates-4/29/2002
54Reuters Business Cellegy Withdraws Pain Drug Application SOUTH SAN FRANCISCO, Cdalroi-4/26/2002
53Drug developers Vertex Pharmaceuticals Inc. (NASDAQ:VRTX) and Aventis SA (SBF:AVElmer-4/24/2002
52Tuesday April 23, 8:05 am Eastern Time Press Release SOURCE: Inflazyme PharmaceuMiljenko Zuanic-4/23/2002
51The sage continue... Tuesday April 23, 4:00 pm Eastern Time Press Release SOURCMiljenko Zuanic-4/23/2002
50MediGene’s Etomoxir project delayed Message 17353548mopgcw-4/19/2002
49MGI PHARMA Stops Phase 3 Irofulven Clinical Trial for Refractory Pancreatic Cancnigel bates-4/17/2002
48Reuters Business Human Genome ends work on one drug, looks at another ROCKVILLEMiljenko Zuanic-4/15/2002
47Mar 28, 2002 /PRNewswire-FirstCall via COMTEX/ -- Watson Pharmaceuticals, Inc. (Elmer-3/28/2002
46Maybe not major, but it is for ISTA... IRVINE, Calif., March 26 /PRNewswire-Firnigel bates-3/26/2002
45NeuroSearch and Grupo Ferrer discontinue the development of NS2710 for the treatmichael_f_murphy-3/22/2002
44Wednesday March 20, 9:15 am Eastern Time Press Release SOURCE: Guilford PharmaceMiljenko Zuanic-3/21/2002
43Bristol-Myer's Heart-Drug Results Deal Blow to Company's Prospects By Rmopgcw-3/20/2002
42Protein Design Labs Announces Results of Phase II Clinical Trial Of Zenapaxdalroi-3/20/2002
41Tuesday March 19, 3:27 pm Eastern Time Common cold drug cuts illness short, makeMiljenko Zuanic-3/19/2002
40Wednesday March 13, 7:03 am Eastern Time Press Release SOURCE: Corixa CorporatioMiljenko Zuanic-3/13/2002
39Thursday March 7, 8:12 am Eastern Time Press Release SOURCE: Sepracor Inc. SepraMiljenko Zuanic-3/7/2002
38Thursday March 7, 7:01 am Eastern Time Press Release SOURCE: Celgene CorporationMiljenko Zuanic-3/7/2002
37Sepracor. (eom)scott_jiminez-3/7/2002
36Wow. I hadn't seen that commentary. Nice call! (eom)scaram(o)uche-3/5/2002
35Tuesday March 5, 3:33 pm Eastern Time Press Release SOURCE: Miravant Medical TecMiljenko Zuanic-3/5/2002
34Message 16964124 Problems persist for some time and Abbott lost confidence. CanMiljenko Zuanic-3/5/2002
33Neurosearch and Glaxo end drug tests By Nerma Jelacic FT.com, 14:22 GMT Mar 5, nigel bates-3/5/2002
32rubitecan. Maybe this does not strictly qualify as immediate failure, but does keokalani'nui-3/5/2002
31Isis Pharmaceuticals Reports Phase II Study Results Of Topical Alicaforsen, ISISmichael_f_murphy-2/25/2002
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News